drugset / Trial / NCT00137813
Avastin and Taxotere for Esophagogastric Cancer
Phase 2
Completed
42 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabGenentech, Inc. · collabMassachusetts General Hospital · collabSanofi · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine what effects (good and bad) bevacizumab (Avastin) and docetaxel (Taxotere), used in combination, have on metastatic gastric and esophageal cancer.
Timeline
- Start
- 2004-08
- Primary completion
- 2006-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Docetaxel | Small molecule | — | Intravenous |